TY - JOUR
T1 - Molecular profiling of biliary tract cancer
T2 - A target rich disease
AU - Jain, Apurva
AU - Javle, Milind
N1 - Publisher Copyright:
© Journal of Gastrointestinal Oncology. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Biliary tract cancers (BTCs) are relatively uncommon orphan tumors that have an aggressive disease course and a poor clinical outcome. Surgery is the only curative treatment, but most patients present with advanced disease and therefore have a limited survival. Gemcitabine and cisplatin based chemotherapy has been the only widely accepted standard systemic therapy regimen in these patients but these tumors can be chemoresistant, further complicating their management. In recent times, there has been considerable research in the genetics of BTC and with the advent of new, advanced technologies like next-generation sequencing (NGS) we are achieving a greater understanding of its disease biology. With the help of NGS, we have now been able to identify actionable mutations such as in the isocitrate dehydrogenase 1 (IDH1), FGFR2, BRAF and HER2/neu genes for targeted therapeutics and correlate the genetic variations with distinct clinical prognoses. This recent genetic information has the potential to make precision medicine a part of routine clinical practice for the management of BTC patients.
AB - Biliary tract cancers (BTCs) are relatively uncommon orphan tumors that have an aggressive disease course and a poor clinical outcome. Surgery is the only curative treatment, but most patients present with advanced disease and therefore have a limited survival. Gemcitabine and cisplatin based chemotherapy has been the only widely accepted standard systemic therapy regimen in these patients but these tumors can be chemoresistant, further complicating their management. In recent times, there has been considerable research in the genetics of BTC and with the advent of new, advanced technologies like next-generation sequencing (NGS) we are achieving a greater understanding of its disease biology. With the help of NGS, we have now been able to identify actionable mutations such as in the isocitrate dehydrogenase 1 (IDH1), FGFR2, BRAF and HER2/neu genes for targeted therapeutics and correlate the genetic variations with distinct clinical prognoses. This recent genetic information has the potential to make precision medicine a part of routine clinical practice for the management of BTC patients.
KW - ARID1A
KW - Biliary tract cancers (BTCs)
KW - FGFR2
KW - Isocitrate dehydrogenase 1 or 2 (IDH1/2)
KW - Next-generation sequencing (NGS)
KW - Overall survival
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85017610003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017610003&partnerID=8YFLogxK
U2 - 10.21037/jgo.2016.09.01
DO - 10.21037/jgo.2016.09.01
M3 - Review article
C2 - 27747093
AN - SCOPUS:85017610003
SN - 2078-6891
VL - 7
SP - 797
EP - 803
JO - Journal of Gastrointestinal Oncology
JF - Journal of Gastrointestinal Oncology
IS - 5
ER -